This is where electrolytes come into the picture
How Major Chains Are Already Responding The national chains that have moved first on GLP-1 adaptation share a common strategic logic: protein-forward positioning, portion optionality, and explicit callouts of nutrient density
Use of SYNJARDY for this indication is supported by evidence from a 26-week double-blind, placebo-controlled clinical trial of empagliflozin, with a double-blind active treatment safety extension period of up to 52 weeks in 157 pediatric patients aged 10 to 17 years with type 2 diabetes mellitus and a pediatric pharmacokinetic study [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)]
Berberine has blood sugar-lowering properties similar to metformin, and combining it with a GLP-1 medication could increase hypoglycemia risk
MDLs are designed to streamline the legal process for large numbers of plaintiffs filing lawsuits involving common factual questions, shared medical evidence, and overlapping allegations against pharmaceutical manufacturers
